Copeptin-994

Test info

  
Copeptin
  
994
  
LAB994
  
MSO
  
ADH
Anti-diuretic hormone
Arginine vasopressin
AVP
Vasopressin
  

Measurement of copeptin levels in plasma

  

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

  • Sepsis, severe sepsis, septic shock, lower respiratory tract infections, chronic obstructive pulmonary disease (COPD), and cardiovascular diseases, i.e., chronic heart failure may increase copeptin concentrations.1-3
  • Arginine vasopressin (AVP) receptor antagonist therapies and other diseases in which AVP has been shown to play an important pathophysiologic role may also increase copeptin concentration
  • Mixed forms of diabetes insipidus (DI) can exist, and both central and peripheral DI may be incomplete, complicating the interpretation of results
  • Patients with long-standing psychogenic polydipsia may have copeptin levels suggestive of mild nephrogenic DI.
  • While an elevated plasma copeptin concentration in a hyponatremic patient can be suggestive of the syndrome of inappropriate antidiuretic hormone secretion (SIADH), copeptin determination alone is not typically sufficient to distinguish SIADH from other hyponatremic disorders.4,5
  • Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedures, may have circulating anti-animal antibodies present. These antibodies may interfere with the assay reagents to produce unreliable results.

Specimen

  
EDTA plasma
  
  
0.5 mL
  
0.3 mL
Submission of the minimum volume does not allow for repeat testing
  

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting

  
  1. Centrifuge sample within 2 hours of collection.
  2. Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp) labelled as EDTA plasma
  

Refrigerated (preferred) - 14 days

Frozen - 14 days

Ambient - 14 days

Freeze/thaw cycles - stable x3

  
  • Gross lipemia
  • Gross hemolysis
  • Gross icterus

Performance

  
LabCorp (010505): R-LC
  
3 - 5 days
  

The ThermoFisher/BRAHMS KRYPTOR® assay employs Time-Resolved Amplified Cryptate Emission Cryptate Emission (TRACE) technology based on a non-radioactive energy transfer between a donor (europium cryptate) and an acceptor (XL665) in a sandwich immunofluorescent format using two mouse monoclonal antibodies.

Clinical and Interpretive info

  

0.0–5.9 pmol/L

Reference interval derived from testing of non-water deprived, non-fasting adults.

Billing

  
84588

Tracking

  
03/22/2019
  
12/20/2023
  
12/20/2023